Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Supplementary baseline data

From: Neutrophil-to-lymphocyte ratio and short-term mortality in patients having anti-MDA5-positive dermatomyositis with interstitial lung disease: a retrospective study

Variables

Total (n = 263)

Survival group (n = 185)

Non-survival group (n = 78)

P-value

Age, median, years

53.0 [48.0,62.0]

51.0[46.0,58.0]

57.0[51.0,63.0]

 < 0.001

Sex (female, n%)

87.0 (33.1)

58.0 (31.4)

29.0 (37.2)

0.359

Smoke, n (%)

38.0 (14.4)

21.0 (11.4)

17.0(21.8)

0.0282

Duration, median, month

2.0[1.0,3.0]

2.0[1.0,4.0]

1.0[0.7,2.0]

 < 0.001

Ferritin, median, ug/L

865.0[366.5,1570.0]

548.2[270.0,1275.8]

1349.0[795.5,2620.4]

 < 0.001

Treatment after admission

 Steroid used, n (%)

56 (21.3%)

10 (5.4%)

46 (59.0%)

 < 0.001

Immunosuppressant used

 CTX, n (%)

64 (24.3%)

20 (10.8%)

24 (30.8%)

 < 0.001

 CsA, n (%)

47 (17.9%)

13 (7.0%)

24 (30.8%)

 < 0.001

 Tac, n (%)

36 (13.7%)

7 (3.8%)

29 (37.2%)

 < 0.001

 Tofacitinib, n (%)

56 (21.3%)

19 (10.3%)

37 (47.4%)

 < 0.001

 IVIG, n (%)

57 (21.7%)

34 (18.4%)

23 (29.5%)

 < 0.001

  1. Abbreviations: CTX cyclophosphamide, CsA cyclosporin A, Tac tacrolimus, IVIG intravenous immune globulin
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us